产品详情
Targets
Target | Value | |
---|---|---|
TIE-2 | ||
hVEGFR2 | IC50: 9nM | |
C-Raf-1 | IC50: 24nM | |
B-RAFV599E | IC50: 76nM | |
c-Abl | IC50: 99nM | |
mVEGF2 | IC50: 165nM | |
RET | IC50: 410nM | |
hVEGFR3 | IC50: 420nM | |
hVEGFR1 | IC50: 820nM | |
c-KIT | IC50: 2.5μM |
In vitro | DMSO | 76 mg/mL (179.08 mM) | |
Water | Insoluble | ||
Ethanol | 18 mg/mL | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 23.58 mL | 117.89 mL | 235.79 mL |
0.5 mM | 4.72 mL | 23.58 mL | 47.16 mL |
1 mM | 2.36 mL | 11.79 mL | 23.58 mL |
5 mM | 0.47 mL | 2.36 mL | 4.72 mL |
*The above data is based on the productmolecular weight 424.1147. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A12693 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 424.1147 |
Formula | C22H15F3N4O2 |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 861875-60-7 |
Synonyms | BAW2881, BAW-2881, BAW 2881, NVP-BAW-2881, NVP-BAW 2881 |
SMILES | O=C(NC1=CC(C(F)(F)F)=CC=C1)C2=CC=CC3=C2C=CC(OC4=CC=NC(N)=N4)=C3 |
产品标签
Product Questions
Product Questions
RAF265 (CHIR-265)
RAF265 (CHIR-265)是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,可控制或正常化VEGFR-2,同时抑制B-raf和c-Raf…
CYC116 (CYC-116)
CYC116 (CYC-116)是一种有效的Aurora A/B抑制剂,Ki为8.0 nM/9.2 nM,对VEGFR2(Ki为44 nM)作用稍弱。
BMS-817378
BMS-817378是Met/VEGFR-2双重抑制剂BMS-794833的新型前药。
Linifanib (ABT-869)
Linifanib (ABT-869)是一种结构新颖的有效RTK,VEGF和PDGF抑制剂,对人内皮细胞,PDGFR-β,KDR和CSF-1R的IC50分别为0.…
ZM 323881 hydrochloride
ZM 323881 hydrochloride是一种有效且选择性的人血管内皮生长因子受体2(VEGFR2/KDR)激酶活性抑制剂。
XL184 free base (Cabozantinib)
XL184 free base (Cabozantinib)是设计用来抑制多种受体酪氨酸激酶(特别是MET和VEGFR2)的小分子。